Abstract Search

ey0016.12-6 | Metabolic Syndrome | ESPEYB16

12.6. Early life adversity with height stunting is associated with cardiometabolic risk in adolescents independent of Body Mass Index

BM Reid , MM Harbin , JL Arend , AS Kelly , DR Dengel , MR Gunnar

To read the full abstract: J Pediatr 2018;202:143149.Summary: In a case control study of 30 post-institutionalized youths compared with 90 age- and BMI percentile-matched youths living in the Minneapolis-Saint Paul metropolitan area, early life stress, as reflected by height-stunted growth in institutional care, was associated with cardiovascular and metabolic risk in yout...

0 shares

ey0019.11-16 | Weight regulation and endocrine circuits (including interventions) | ESPEYB19

11.16. Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial

CK Fox , JM Clark , KD Rudser , JR Ryder , AC Gross , BM Nathan , M Sunni , DR Dengel , CJ Billington , MO Bensignor , AS Kelly

Lusc0001@umn.edu Obesity (Silver Spring) 2022, 30(5):11051115. https://doi.org/10.1002/oby.23395Brief Summary: This 52-week randomised placebo-controlled trial showed that exenatide XR improves stabilisation of BMI reduction after lifestyle intervention in adolescents with obesity.Maintaining weight loss after an in...

0 shares

ESPE Yearbook of Paediatric Endocrinology

12.6. Early life adversity with height stunting is associated with cardiometabolic risk in adolescents independent of Body Mass Index

11.16. Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial

BiosciAbstracts